Navigation Links
Banning the drug Valdecoxib In India

The National Pharmaco Vigilance Advisory Committee has prohibited the sale and manufacture of the drug// Valdecoxib, indicated for arthritis and acute pain in India under the Drugs and Cosmetics Act.

Studies done abroad have indicated that the drug Valdecoxib is found to double the risk of heart attacks and strokes and also result in severe skin reactions.

Although some of the leading pharmaceutical companies have stopped manufacturing it and have withdrawn the drug from the Indian market, a few leading companies differ in opinion and have adopted a “wait and watch” approach as a result of which they have still not withdrawn the drug from the market.

Some of the leading drugs manufacturing companies in India also have a major market-share in the product, with sales amounting to Rs.25 crore another reason for their reluctance to withdraw the drug from the market.

According to US officials, the request for withdrawal of the drug was made by the FDA after seeking approval from a committee they had constituted for advice on the issue. Higher authorities in the Indian Drug Manufacturers Association however feel that based on US models, the drug should not be banned in India as each countries requirement are different and withdrawal and approval of drugs should be made accordingly.

'"/>




Page: 1

Related medicine news :

1. Banning Smoking in the Home Helps Infants
2. Doctors Ask MPs To Protect Human Rights By Banning Smoking In Enclosed Public Spaces
3. Punjab Plans of Banning Sex Determination Kit from US
4. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
5. Is Diabetes the Leading Cause of Kidney Failure in India
6. AIDS Disaster in India is Imminent
7. Indian Prime Minister has successful Knee Replacement Surgery
8. International community warns India on HIV situation
9. India takes on foot-and-mouth disease by vaccinating animals
10. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
11. India to benefit from pharma companies move
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... Valley, CA (PRWEB) , ... December 07, 2016 , ... ... be used in several ways to restore a more youthful appearance to the face. ... now offer Sculptra, along with a variety of other treatments, to rejuvenate and renew ...
(Date:12/7/2016)... ... ... When it came time to blow out his candles on his 14th birthday, Estefano Reano ... Transplant team at Joe DiMaggio Children’s Hospital surprised his family with a phone call ... recipient. , “He was playing at home, when we got the phone call telling ...
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, ... families and business owners in the greater Dallas metropolitan area, is announcing a ... Officer Foundation. , Established in 2009 by active police professionals in the Dallas ...
(Date:12/7/2016)... , ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December ... ... another mystery. A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia ... occur in dogs. The study was published in the prestigious Journal of Veterinary ...
(Date:12/7/2016)... Phoenix, Arizona (PRWEB) , ... December 07, 2016 , ... ... Juvederm®, Just in Time For The Holiday Party Season. Save Up To 33% Off ... and Laser Salon is providing the Phoenix Valley with Delightful Deals on ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Global Hospital Linen Supply and Management Services Market: ... supply and management services market presents a comprehensive analysis ... regional level. The study provides historic data of 2015 ... 2024 based on revenue (US$ Bn). The drivers and ... their impact on demand during the forecast period have ...
(Date:12/7/2016)... Dec. 7, 2016  Palatin Technologies, Inc. ("Palatin") ... on a previously disclosed underwritten public offering of ... acted as sole book-running manager, Roth Capital Partners ... acted as co-manager for the offering. ... in net proceeds, allowing us to continue advancing ...
(Date:12/7/2016)... 2016  Northwest Biotherapeutics (Nasdaq: NWBO ... company developing DCVax® personalized immune therapies for solid ... has not accepted the Company,s plan of remediation ... and the Company has notified Nasdaq of its ... from listing on Nasdaq.  Upon withdrawal from Nasdaq, ...
Breaking Medicine Technology: